215 related articles for article (PubMed ID: 25492239)
1. Silibinin and its 2,3-dehydro-derivative inhibit basal cell carcinoma growth via suppression of mitogenic signaling and transcription factors activation.
Tilley C; Deep G; Agarwal C; Wempe MF; Biedermann D; Valentová K; Kren V; Agarwal R
Mol Carcinog; 2016 Jan; 55(1):3-14. PubMed ID: 25492239
[TBL] [Abstract][Full Text] [Related]
2. Silibinin inhibits UVB- and epidermal growth factor-induced mitogenic and cell survival signaling involving activator protein-1 and nuclear factor-kappaB in mouse epidermal JB6 cells.
Singh RP; Dhanalakshmi S; Mohan S; Agarwal C; Agarwal R
Mol Cancer Ther; 2006 May; 5(5):1145-53. PubMed ID: 16731746
[TBL] [Abstract][Full Text] [Related]
3. Silibinin meglumine, a water-soluble form of milk thistle silymarin, is an orally active anti-cancer agent that impedes the epithelial-to-mesenchymal transition (EMT) in EGFR-mutant non-small-cell lung carcinoma cells.
Cufí S; Bonavia R; Vazquez-Martin A; Corominas-Faja B; Oliveras-Ferraros C; Cuyàs E; Martin-Castillo B; Barrajón-Catalán E; Visa J; Segura-Carretero A; Bosch-Barrera J; Joven J; Micol V; Menendez JA
Food Chem Toxicol; 2013 Oct; 60():360-8. PubMed ID: 23916468
[TBL] [Abstract][Full Text] [Related]
4. Silibinin inhibits cytokine-induced signaling cascades and down-regulates inducible nitric oxide synthase in human lung carcinoma A549 cells.
Chittezhath M; Deep G; Singh RP; Agarwal C; Agarwal R
Mol Cancer Ther; 2008 Jul; 7(7):1817-26. PubMed ID: 18644994
[TBL] [Abstract][Full Text] [Related]
5. Silymarin inhibits growth and causes regression of established skin tumors in SENCAR mice via modulation of mitogen-activated protein kinases and induction of apoptosis.
Singh RP; Tyagi AK; Zhao J; Agarwal R
Carcinogenesis; 2002 Mar; 23(3):499-510. PubMed ID: 11895866
[TBL] [Abstract][Full Text] [Related]
6. Silibinin modulates TNF-α and IFN-γ mediated signaling to regulate COX2 and iNOS expression in tumorigenic mouse lung epithelial LM2 cells.
Tyagi A; Agarwal C; Dwyer-Nield LD; Singh RP; Malkinson AM; Agarwal R
Mol Carcinog; 2012 Oct; 51(10):832-42. PubMed ID: 21882257
[TBL] [Abstract][Full Text] [Related]
7. Differential responses of skin cancer-chemopreventive agents silibinin, quercetin, and epigallocatechin 3-gallate on mitogenic signaling and cell cycle regulators in human epidermoid carcinoma A431 cells.
Bhatia N; Agarwal C; Agarwal R
Nutr Cancer; 2001; 39(2):292-9. PubMed ID: 11759294
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms and preclinical efficacy of silibinin in preventing skin cancer.
Singh RP; Agarwal R
Eur J Cancer; 2005 Sep; 41(13):1969-79. PubMed ID: 16084079
[TBL] [Abstract][Full Text] [Related]
9. Silibinin inhibits inflammatory and angiogenic attributes in photocarcinogenesis in SKH-1 hairless mice.
Gu M; Singh RP; Dhanalakshmi S; Agarwal C; Agarwal R
Cancer Res; 2007 Apr; 67(7):3483-91. PubMed ID: 17409458
[TBL] [Abstract][Full Text] [Related]
10. Silibinin inhibits constitutive and TNFalpha-induced activation of NF-kappaB and sensitizes human prostate carcinoma DU145 cells to TNFalpha-induced apoptosis.
Dhanalakshmi S; Singh RP; Agarwal C; Agarwal R
Oncogene; 2002 Mar; 21(11):1759-67. PubMed ID: 11896607
[TBL] [Abstract][Full Text] [Related]
11. Silibinin suppresses growth of human colorectal carcinoma SW480 cells in culture and xenograft through down-regulation of beta-catenin-dependent signaling.
Kaur M; Velmurugan B; Tyagi A; Agarwal C; Singh RP; Agarwal R
Neoplasia; 2010 May; 12(5):415-24. PubMed ID: 20454513
[TBL] [Abstract][Full Text] [Related]
12. Inhibitory effect of silibinin on EGFR signal-induced renal cell carcinoma progression via suppression of the EGFR/MMP-9 signaling pathway.
Liang L; Li L; Zeng J; Gao Y; Chen YL; Wang ZQ; Wang XY; Chang LS; He D
Oncol Rep; 2012 Sep; 28(3):999-1005. PubMed ID: 22736024
[TBL] [Abstract][Full Text] [Related]
13. Oral silibinin inhibits lung tumor growth in athymic nude mice and forms a novel chemocombination with doxorubicin targeting nuclear factor kappaB-mediated inducible chemoresistance.
Singh RP; Mallikarjuna GU; Sharma G; Dhanalakshmi S; Tyagi AK; Chan DC; Agarwal C; Agarwal R
Clin Cancer Res; 2004 Dec; 10(24):8641-7. PubMed ID: 15623648
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic efficacy of silibinin on human neuroblastoma cells: Akt and NF-κB expressions may play an important role in silibinin-induced response.
Yousefi M; Ghaffari SH; Soltani BM; Nafissi S; Momeny M; Zekri A; Behmanesh M; Alimoghaddam K; Ghavamzadeh A
Neurochem Res; 2012 Sep; 37(9):2053-63. PubMed ID: 22717697
[TBL] [Abstract][Full Text] [Related]
15. Silibinin protects against photocarcinogenesis via modulation of cell cycle regulators, mitogen-activated protein kinases, and Akt signaling.
Mallikarjuna G; Dhanalakshmi S; Singh RP; Agarwal C; Agarwal R
Cancer Res; 2004 Sep; 64(17):6349-56. PubMed ID: 15342425
[TBL] [Abstract][Full Text] [Related]
16. Silibinin inhibits cell growth and induces apoptosis by caspase activation, down-regulating survivin and blocking EGFR-ERK activation in renal cell carcinoma.
Li L; Gao Y; Zhang L; Zeng J; He D; Sun Y
Cancer Lett; 2008 Dec; 272(1):61-9. PubMed ID: 18723275
[TBL] [Abstract][Full Text] [Related]
17. Chemopreventive effects of silymarin and silibinin on N-butyl-N-(4-hydroxybutyl) nitrosamine induced urinary bladder carcinogenesis in male ICR mice.
Tyagi A; Raina K; Singh RP; Gu M; Agarwal C; Harrison G; Glode LM; Agarwal R
Mol Cancer Ther; 2007 Dec; 6(12 Pt 1):3248-55. PubMed ID: 18089718
[TBL] [Abstract][Full Text] [Related]
18. Targeting silibinin in the antiproliferative pathway.
Li L; Zeng J; Gao Y; He D
Expert Opin Investig Drugs; 2010 Feb; 19(2):243-55. PubMed ID: 20047507
[TBL] [Abstract][Full Text] [Related]
19. Silibinin efficacy against human hepatocellular carcinoma.
Varghese L; Agarwal C; Tyagi A; Singh RP; Agarwal R
Clin Cancer Res; 2005 Dec; 11(23):8441-8. PubMed ID: 16322307
[TBL] [Abstract][Full Text] [Related]
20. Effect of silibinin on the growth and progression of primary lung tumors in mice.
Singh RP; Deep G; Chittezhath M; Kaur M; Dwyer-Nield LD; Malkinson AM; Agarwal R
J Natl Cancer Inst; 2006 Jun; 98(12):846-55. PubMed ID: 16788158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
